Isomorphic Labs says AI could design all drugs, but its work remains preclinical
Isomorphic Labs President Max Jaderberg said AI could eventually be used to design all medicines. The company’s drug-development efforts remain in preclinical testing, with no timeline given for human trials.
Key points
- Isomorphic Labs’ AI-designed drug efforts are still in preclinical testing
- Jaderberg declined to give a timeline for human trials
- The company is pursuing drugs for cancer, immune-related conditions and inflammatory diseases
- Isomorphic has research partnerships with Novartis, Johnson & Johnson and Eli Lilly
Sources
- Business InsiderRead ↗Google spinoff Isomorphic Labs is in a race to shake up the long, painful road to cancer-beating drugs
- BloombergRead ↗Isomorphic Labs President Says AI Will Design All Drugs One Day
- BloombergRead ↗How AI Is Changing Drug Discovery at Isomorphic Labs
- BloombergRead ↗Isomorphic Labs in Talks for About $5 Billion in Funding
Details
Speaking at Bloomberg Tech in London, Jaderberg described Isomorphic as being in its “first innings” and said its efforts to use AI for drug discovery remain preclinical. Business Insider reports that he declined to provide a timeline for clinical trials, though he said the company had not experienced new delays and had been building a clinical development team in Boston.
Business Insider reports that Isomorphic unveiled a drug design engine in February, which the company says improves on AlphaFold. Jaderberg said the company is using its models to develop drugs for cancer, immune-related conditions and inflammatory diseases; Isomorphic has also formed research partnerships with Novartis, Johnson & Johnson and Eli Lilly.
Written from coverage as of
Images
- Business Insider
- Bloomberg
Stocks in this story
Change since open: 20 Nov to 21 Nov 2026
Last refresh